Cargando…
Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
BACKGROUND: Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. METHODS: Nationwi...
Autores principales: | Lin, E., Garmo, Hans, Van Hemelrijck, Mieke, Adolfsson, Jan, Stattin, Pär, Zethelius, Björn, Crawley, Danielle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607667/ https://www.ncbi.nlm.nih.gov/pubmed/34809595 http://dx.doi.org/10.1186/s12885-021-08941-y |
Ejemplares similares
-
Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022) -
Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022) -
Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study
por: Crawley, Danielle, et al.
Publicado: (2018) -
Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016) -
Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
por: Lin, E., et al.
Publicado: (2020)